StockData
GRAIL, Inc. logo

GRAIL, Inc. (GRAL) company profile

GRALNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$105.88+0.28 (+0.27%)

Close on Nov 17, 2026Market cap $4.73BP/E –Yield –

About Grail

Services-Medical Laboratories, SIC 8071

The company is a commercial-stage healthcare organization focused on multi-cancer early detection at population scale. Its core offering is Galleri, a multi-cancer early detection screening blood test designed to screen for over 50 cancer types by analyzing cell-free DNA methylation patterns and predicting the cancer signal of origin. Beyond asymptomatic population screening, the business offers a research-use-only targeted methylation platform with customizable classifiers for biopharmaceutical and oncology therapeutics partners, supporting precision oncology applications such as biomarker discovery, prognosis, and recurrence monitoring. Its customer base includes healthcare systems, self-insured employers, digital health platforms, health insurers, life insurance providers, and biopharmaceutical developers.

The company processes commercial and clinical tests through an accredited high-capacity laboratory capable of processing up to one million tests per year, having processed over 800,000 tests across clinical and commercial settings. Operating primarily in the United States, it has initiated international expansion into select markets such as Canada and Israel through distributor partnerships, with plans to enter South Korea and potential future deployment with the National Health Service in the United Kingdom. The provided text does not state the location of the company's headquarters.

Summary of the business section of Grail's latest annual report, written by StockData.

Company profile

Company

Legal name
GRAIL, Inc.
Founded
2016
Headquarters
Sunnyvale, CA
Address
250 S. Mathilda Avenue, Suite 100 94086
Phone
(833) 694-2553
Website
grail.com
Employees
910, Dec 31, 2025
Industry
Services-Medical Laboratories
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, San Mateo, California

Stock & identifiers

Ticker
GRAL
Exchange
Nasdaq
IPO date
Jun 12, 2024
Shares outstanding
45M, Aug 3, 2026
Public float
$1.90B, Jun 30, 2025
Filer category
Non-accelerated filer<br>Emerging growth company
SEC CIK
1699031
CUSIP
384747101
ISIN
US3847471014
FIGI
BBG01N6CGW43
Share class FIGI
BBG01N6CGX05
LEI
2549009XSNESW3VE8024
EIN
86-3673636

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Joshua J. OfmanChief Executive Officer, Director342,271
Robert P. RagusaChief Executive Officer, Director518,582
Aaron FreidinChief Financial Officer222,364
Andrew John PartridgeChief Growth Officer155,865
William J. ChaseDirector43,131
Steven MizellDirector42,978
Gregory L. SummeDirector45,909
Sarah KrevansDirector42,628

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsIncentive payOtherTotalvs. prior year
Robert Ragusa
Chief Executive Officer
$785.00K–$6.48M$778.09K$53.31K$8.09M+6%
Aaron Freidin
Chief Financial Officer
$560.00K$250.00K$2.00M$321.94K$3.00K$3.13M-15%
Joshua Ofman
President
$655.00K–$3.19M$376.56K$92.43K$4.32M-26%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had approximately 910 full-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jun 12, 2024Name changeName changed from GRAIL, LLC to GRAIL, Inc.
May 6, 2024Spin-offRegistration as a new public company (Form 10), e.g. spin-off

See a number that looks wrong?